Journal Thoracic Oncology
WCLC2016-Abstract-Book_vF-WEB_revNov17-1
WCLC2016-Abstract-Book_vF-WEB_revNov17-1
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Abstracts <strong>Journal</strong> of <strong>Thoracic</strong> <strong>Oncology</strong> • Volume 12 Issue S1 January 2017<br />
a decision to operate and will propose a controversial algorithm for surgical<br />
treatment of N2 disease [5]. 2.Intraoperative We will discuss the arguments<br />
surrounding the necessary extent of intraoperative lymph node dissection.<br />
We will consider the relative merits of the methods for intraoperative<br />
sentinel node identification including Near Infrared thoracoscopy and<br />
radiolabelling [6,7]. We will ask whether the investment in technology and<br />
time is beneficial for the patient. Is the added information about metastases<br />
of clinical value ? We will evaluate the argument between nodal sampling vs<br />
systematic nodal dissection [8] and attempt to formulate an intraoperative<br />
mapping algorithm. Intraoperative nodal mapping has been proposed as a<br />
prerequisite to direct the extent of lung resection. We will examine how the<br />
findings of nodal disease have been used to discriminate between lobectomy<br />
vs pneumonectomy or between lobectomy vs segmentectomy. We will<br />
consider the argument that nodal metastatic disease is not a justification<br />
for more extensive sacrifice of functioning lung tissue. Is there any role<br />
for intraoperative nodal analysis in determining the extent of resection?<br />
How reliable is this method of nodal mapping. 3.Postoperative Once the<br />
pathologist has the resected lymph nodes we will attempt to rationalize<br />
how they should be analysed, asking the question : “ What are the minimum<br />
sampling requirements ?”. We will also analyse whether the more detailed<br />
nodal mapping of micrometastatic disease by immunohistochemistry<br />
significantly influences patient management or outcome [10] ? Finally we will<br />
discuss how these pathological results could influence the use of adjuvant<br />
chemotherapy/ radiotherapy or more interestingly targeted therapies. We<br />
intend the session to be interactive between presenters and delegates with<br />
a free exchange of ideas and experience. We hope to stimulate delegates<br />
to re-evaluate their own approach to lung cancer staging.References 1.<br />
Chang DB, Yang PC, Yu CJ, Kuo SH, Lee YC, Luh KT.Ultrasonography and<br />
ultrasonographically guided fine-needle aspiration biopsy of impalpable<br />
cervical lymph nodes in patients with non-small cell lung cancer.Cancer. 1992<br />
Sep 1;70(5):1111-4 2. Suga K, Yuan Y, Ueda K, Kaneda Y, Kawakami Y, Zaki M,<br />
Matsunaga N Computed tomography lymphography with intrapulmonary<br />
injection of iopamidol for sentinel lymph node localization. Invest Radiol.<br />
2004 Jun;39(6):313-24. 3. Annema JT, van Meerbeeck JP, Rintoul RC, Dooms C,<br />
Deschepper E, Dekkers OM, De Leyn P, Braun J, Carroll NR, Praet M, de Ryck F,<br />
Vansteenkiste J, Vermassen F, Versteegh MI, Veseliç M, Nicholson AG, Rabe<br />
KF, Tournoy KG. Mediastinoscopy vs endosonography for mediastinal nodal<br />
staging of lung cancer: a randomized trial .JAMA. 2010 Nov 24;304(20):2245-<br />
52 4. Witte B, Hürtgen M.Video-assisted mediastinoscopic lymphadenectomy<br />
(VAMLA).J Thorac Oncol. 2007 Apr;2(4):367-9 5. De Leyn P, Dooms C, Kuzdzal J,<br />
Lardinois D, Passlick B, Rami-Porta R, Turna A, Van Schil P, Venuta F, Waller D,<br />
Weder W, Zielinski M. Revised ESTS guidelines for preoperative mediastinal<br />
lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg.<br />
2014 May;45(5):787-98 6. Hachey KJ, Colson YL. Current innovations in<br />
sentinel lymph node mapping for the staging and treatment of resectable<br />
lung cancer. Semin Thorac Cardiovasc Surg. 2014 Autumn;26(3):201-9 7.<br />
Tomoshige K, Tsuchiya T, Otsubo R, Oikawa M, Yamasaki N, Matsumoto K,<br />
Miyazaki T, Hayashi T, Kinoshita N, Nanashima A, Nagayasu T.Intraoperative<br />
diagnosis of lymph node metastasis in non-small-cell lung cancer by a semi-dry<br />
dot-blot method.Eur J Cardiothorac Surg. 2016 Feb;49(2):617-22 8. Darling<br />
GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, Jones DR,<br />
McKenna RJ, Landreneau RJ, Rusch VW, Putnam JB Jr. Randomized trial of<br />
mediastinal lymph node sampling versus complete lymphadenectomy during<br />
pulmonary resection in the patient with N0 or N1 (less than hilar) non-small<br />
cell carcinoma: results of the American College of Surgery <strong>Oncology</strong> Group<br />
Z0030 Trial . J Thorac Cardiovasc Surg. 2011 Mar;141(3):662-70 9. Nomori H,<br />
Cong Y, Sugimura H. Utility and pitfalls of sentinel node identification using<br />
indocyanine green during segmentectomy for cT1N0M0 non-small cell lung<br />
cancer. Surg Today. 2016 Aug;46(8):908-13 10. Deng XF, Jiang L, Liu QX, Zhou D,<br />
Hou B, Cui K, Min JX, Dai JG Lymph node micrometastases are associated with<br />
disease recurrence and poor survival for early-stage non-small cell lung cancer<br />
patients: a meta-analysis. J Cardiothorac Surg. 2016 Feb 16;11:28.<br />
Keywords: lung cancer. lymph node metastasis. nodal mapping<br />
SESSION MTE16: PRECISION MEDICINE IN NSCLC: LESSONS<br />
LEARNED AND PERSPECTIVES (TICKETED SESSION)<br />
TUESDAY, DECEMBER 6, 2016 - 07:30-08:30<br />
MTE16.02 PRECISION MEDICINE IN NSCLC: LESSONS LEARNED<br />
AND PERSPECTIVES<br />
Christian Manegold<br />
Surgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim/Germany<br />
Medical therapy in advanced NSCLC in 2016 is characterized by<br />
personalization, individualization, and therapy precision. Not only clinical<br />
factors are used for treatment differentiation but also the histological<br />
type (squamous versus non-squamous) and the molecular profile (mutant<br />
versus wild type). In addition, the complexity of the treatment algorithm has<br />
gradually increased over time by the incorporation of a number of approved<br />
molecules for 1 st , 2 nd -, subsequent line therapy (Peters, 2012; Masters, 2015;<br />
NCCN, 2016). NSCLC – 1 st -line-therapy - wild-type: For patients with wild-type<br />
non-squamous NSCLC it is generally accepted that upfront platinum based<br />
doublet chemotherapy (DCT) remains the backbone for individuals with<br />
good performance and that this approach should be modified according to<br />
feasibility and tolerability, co-morbidity, and age over 70 years. Progress<br />
has been made through pemetrexed, which is recommended as the favorite<br />
partner of platinum-based components (Scagliotti; 2008/2011). In addition, it<br />
has lately been demonstrated that the extension of induction chemotherapy<br />
by single agent pemetrexed until progression - in case of non-progression<br />
under four cycles of DCT not containing pemetrexed (switch maintenance)<br />
(Ciuleanu, 2009) or containing pemetrexed (continuation maintenance)<br />
(Paz-Ares, 2012/2013) - prolongs survival. In this case survival may also be<br />
prolonged by erlotinib, when used in the switch maintenance setting, but<br />
erlotinib’s benefit seem to be restricted to patients, which have experienced<br />
disease stabilization to induction chemotherapy (Cappuzzo, 2010; Coudert,<br />
2012). Bevacizumab, when added to platinum-based to DCT, significantly<br />
improves response rate, progression free survival, as well as overall survival<br />
in eligible patients (Sandler, 2006/2010; Reck, 2009/2010). In wild-type<br />
squamous NSCLC platinum based DCT (no pemetrexed, no bevacizumab)<br />
remains standard. Nonetheless, necitumumab has recently shown to<br />
improve survival when combined with cisplatin/gemcitabine (Thatcher,<br />
2015). Maintenance therapy in squamous tumors with docetaxel or erlotinib<br />
(switch) or gemcitabine (continuation) may be justified in some patients even<br />
so study evidence is weaker than for non-squamous tumors (Fidas, 2009;<br />
Perol, 2012). NSCLC – 1 st -line-therapy - mutant: For patients with advanced<br />
NSCLC expressing specific molecular features – mainly non-squamous tumors<br />
– 1 st - line treatment with targeted agents has been established. In tumors<br />
with EGFR mutations gefitinib, erlotinib, and afatinib have shown to prolong<br />
progression free survival over standard chemotherapy (Mok, 2009; Rosell,<br />
2012; Sequist, 2013). In tumors bearing ALK-/ROS1-gene-rearrangements<br />
crizotinib has also shown to prolong progression free survival when<br />
compared to platinum/pemetrexed. (Solomon, 2014). Therefore, erlotinib,<br />
gefitinib or afatinib should be prescribed for patients with tumors bearing<br />
EGFR-mutations. For patients with tumors bearing ALK-/ROS1 crizotinib<br />
should be prescribed. However, for these patients molecular testing is<br />
critical and should be used to select patients for EGFR/ALK/ROS1 targeted<br />
therapy. Patients with lung adenocarcinoma should not be excluded from<br />
testing on the basis of clinical characteristics (ethnicity, gender, smoking<br />
status) (Lindeman, 2013). NSCLC - 2 nd /subsequent-line therapy - wild-type:<br />
In patients with disease progression during or after completion of 1 st -line<br />
chemotherapy, 2 nd -, subsequent-line therapy is indicated when the patient<br />
remains in good clinical condition. Approved older treatment options<br />
include docetaxel, pemetrexed and erlotinib. Two anti-angiogenic agents<br />
and two immune-checkpoint inhibitors have recently been added. These<br />
include nintedanib and ramucirumab (Reck, 2014; Thatcher, 2015), as well<br />
as nivolumab and pembrolizumab (Brahmer, 2015; Borghaei, 2015; Herbst,<br />
2016). Nintedanib/docetaxel increases significantly survival in patients with<br />
adenocarcinoma who specifically progressed within 9 months after the<br />
start of 1 st -line therapy, who have experienced disease progression as best<br />
response to 1 st -line therapy and decreases tumor burden and decelerates<br />
tumor growth. Nintedanib/docetaxel has been approved in the EU for the<br />
treatment of patients with adenocarcinoma. Ramucirumab/docetaxel has<br />
also been approved in the US and EU for patients with disease progression on<br />
or after DCT for wild-type non-squamous and squamous NSCLC. This approval<br />
has been based on phase III study evidence indicating survival advantage<br />
in non-squamous NSCLC (statistically significant) and squamous NSCLC<br />
(numerically longer). Comparing head-to head nivolumab and docetaxel in<br />
patients with squamous and non-squamous NSCLC after failure of DCT has<br />
demonstrated superior overall survival in patients receiving nivolumab.<br />
Nivolumab has received US and EU approval for advanced NSCLC with<br />
progression on or after DCT. Nivolumab appears to be most effective in<br />
patients with more than 6 months from completion of the latest treatment<br />
regimen to randomization in comparison to patients with less than 3 months<br />
to randomization. Pembrolizumab has received approval in the US and EU<br />
for patients with advanced NSCLC who’s tumors expressed PD-L1 and who<br />
have disease progression on or after chemotherapy. Approval has been based<br />
on head-to-head comparison of pembrolizumab and docetaxel in patients<br />
with previously treated PD-L1 positive squamous and non-squamous NSCLC,<br />
which has demonstrated a significant survival benefit for pembrolizumab.<br />
NSCLC-2 nd /subsequent-line therapy - mutant: Resistance to first and second<br />
generation EGFR-TKIs is a multifactorial process with a variety of clinically<br />
patterns. Its management requires different, case adapted approaches.<br />
Several strategies are currently under investigation, but some have already<br />
find its way into todays practice although study evidence is still rather weak.<br />
In case of oligoprogression the EGFR-TKI therapy may continue but local<br />
therapies (radiation, surgery) should be added. In case of diffuse progression<br />
EGFR-TKI therapy may continue, but in combination with chemotherapy;<br />
EGFR-TKI therapy may be switched to chemotherapy, but at the moment<br />
of chemotherapy resistance patients may be re-exposed to EGFR-TKI<br />
therapy; admission to clinical trials offering investigational agents may be<br />
a valid option for some patient. Osimertinib has just been approved and is<br />
Copyright © 2016 by the International Association for the Study of Lung Cancer<br />
S85